» Articles » PMID: 4432914

Electrolyte and Morphologic Alterations of Myocardium in Adriamycin-treated Rabbits

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 1974 Dec 1
PMID 4432914
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Rabbits receiving adriamycin (ADR) on a chronic schedule developed significant histopathologic, ultrastructural and tissue electrolyte alterations of the ventricular myocardium. Rabbits that developed clinicopathologic evidence of cardiomyopathy with ADR had histologic lesions of the myocardium, including perivascular fibrosis, interstitial fibrosis and edema and myocytolysis. Ultrastructurally, large vacuoles resembling distended sarcoplasmic reticulum displaced the contractile elements and mitochondria, which were diminished in number within affected myocytes. Frequently, mitochondria appeared as electron-dense structures surrounded by layers of membranes resembling myelin figures. In addition, rabbits with cardiomyopathy had marked elevations in ventricular Ca, Na and H(2)O concentrations. Serum electrolytes were not significantly elevated, but lactic dehydrogenase (LDH) and creatine phosphokinase (CPK) were significantly increased, indicative of a cardiomyopathy. Rabbits receiving ADR but not developing clinicopathologic evidence of heart failure also had significant elevations in ventricular Ca, Na and H(2)O. Rabbits with no cardiomyopathy had no increases either in serum electrolyte concentrations or CPK and LDH levels. These studies indicate that marked increases in ventricular tissue Ca precede and accompany morphologic evidence of chronic myocardial degeneration and may be instrumental in the development of the ADR-induced cardiomyopathy.

Citing Articles

Calcium Overload or Underload? The Effects of Doxorubicin on the Calcium Dynamics in Guinea Pig Hearts.

Wu J, Gao L, Fan H, Liu D, Lin M, Zhu M Biomedicines. 2022; 10(9).

PMID: 36140298 PMC: 9496179. DOI: 10.3390/biomedicines10092197.


Cardioprotective effects of dantrolene in doxorubicin-induced cardiomyopathy in mice.

Azam M, Chakraborty P, Bokhari M, Dadson K, Du B, Masse S Heart Rhythm O2. 2022; 2(6Part B):733-741.

PMID: 34988524 PMC: 8710625. DOI: 10.1016/j.hroo.2021.08.008.


Acute and Delayed Doxorubicin-Induced Myocardiotoxicity Associated with Elevation of Cardiac Biomarkers, Depletion of Cellular Antioxidant Enzymes, and Several Histopathological and Ultrastructural Changes.

Abdelatty A, Ahmed M, Abdel-Kareem M, Dmerdash M, Mady R, Saad A Life (Basel). 2021; 11(9).

PMID: 34575029 PMC: 8467687. DOI: 10.3390/life11090880.


Molecular mechanisms of anthracycline cardiovascular toxicity.

Narezkina A, Narayan H, Zemljic-Harpf A Clin Sci (Lond). 2021; 135(10):1311-1332.

PMID: 34047339 PMC: 10866014. DOI: 10.1042/CS20200301.


Mitochondria-associated protein LRPPRC exerts cardioprotective effects against doxorubicin-induced toxicity, potentially via inhibition of ROS accumulation.

Tang Q, Xiong W, Ke X, Zhang J, Xia Y, Liu D Exp Ther Med. 2020; 20(4):3837-3845.

PMID: 32855734 PMC: 7444327. DOI: 10.3892/etm.2020.9111.


References
1.
Rosalki S . An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med. 1967; 69(4):696-705. View

2.
Tan C, Tasaka H, Yu K, Murphy M, KARNOFSKY D . Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967; 20(3):333-53. DOI: 10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k. View

3.
MARAL R, BOURAT G, DUCROT R, FOURNEL J, GANTER P, JULOU L . [Toxicologic study and experimental antitumor activity of rubidomycin (13,057 R.P.)]. Pathol Biol. 1967; 15(19):903-8. View

4.
Bonadonna G, Monfardini S . Cardiac toxicity of daunorubicin. Lancet. 1969; 1(7599):837. View

5.
Di Marco A, Gaetani M, SCARPINATO B . Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969; 53(1):33-7. View